(Q42436743)

English

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers

scientific article published on 4 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 October 2017

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers (English)

1 reference

Europe PubMed Central

31 October 2017

4

1 reference

Europe PubMed Central

31 October 2017

author name string

Laura Stumm

1

1 reference

Europe PubMed Central

31 October 2017

Lia Burkhardt

2

1 reference

Europe PubMed Central

31 October 2017

Stefan Steurer

3

1 reference

Europe PubMed Central

31 October 2017

Meike Adam

5

1 reference

Europe PubMed Central

31 October 2017

Andreas Becker

6

1 reference

Europe PubMed Central

31 October 2017

Guido Sauter

7

1 reference

Europe PubMed Central

31 October 2017

Sarah Minner

8

1 reference

Europe PubMed Central

31 October 2017

Thorsten Schlomm

9

1 reference

Europe PubMed Central

31 October 2017

Hüseyin Sirma

10

1 reference

Europe PubMed Central

31 October 2017

Uwe Michl

11

1 reference

Europe PubMed Central

31 October 2017

language of work or name

0 references

publication date

4 April 2013

1 reference

Europe PubMed Central

31 October 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Journal of Clinical Pathology

1 reference

Europe PubMed Central

31 October 2017

66

1 reference

Europe PubMed Central

31 October 2017

7

1 reference

Europe PubMed Central

31 October 2017

563-568

1 reference

Europe PubMed Central

31 October 2017

Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Integrative genomic profiling of human prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

FoxP4, a novel forkhead transcription factor

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Genetics of speech and language disorders

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Multiple modes of chromatin remodeling by Forkhead box proteins

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Multiple transcription start sites for FOXP2 with varying cellular specificities

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Bone marrow microenvironment and the identification of new targets for myeloma therapy

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

The transcriptional corepressor CtBP: a foe of multiple tumor suppressors

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Role of the TMPRSS2-ERG gene fusion in prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Transcriptome sequencing to detect gene fusions in cancer

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Molecular classification of prostate cancer using curated expression signatures

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201335

21 January 2018

Identifiers

10.1136/JCLINPATH-2012-201335

1 reference

Europe PubMed Central

31 October 2017

1 reference

Europe PubMed Central

31 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42436743&oldid=1944912859"